Ultivue
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Ultivue was a Cambridge, Massachusetts life science company founded in 2015 that built multiplex immunofluorescence tools for tissue biomarker research. Its InSituPlex assays and the AI-powered STARVUE spatial analysis platform let researchers map multiple proteins and biomarkers on a single tissue slide with subcellular precision, serving biopharma and translational research customers. The company's technology was licensed from Harvard University and the California Institute of Technology, and it was co-founded with involvement from Illumina co-founder David R. Walt.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Founded
Ultivue was founded in Cambridge, Massachusetts, built on DNA-PAINT and DNA-Exchange super-resolution microscopy research licensed from Harvard University and Caltech.
- Series A
The company closed a $5.15 million Series A led by ARCH Venture Partners to commercialize its multiplex reagent kits for tissue-based biomarker research.
- Series C
Ultivue closed a $22 million Series C led by Northpond Ventures to expand its UltiMapper portfolio and its presence in Asia and other international markets.
- Merger with Vizgen
Ultivue merged with spatial genomics company Vizgen to form a single spatial multiomics organization; former Ultivue CEO Rob Carson became president and CEO of the combined Vizgen, and the Ultivue brand was folded under the Vizgen umbrella.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.